. Moreover, the association between cigarette smoking and p53 gene mutations or overexpression in HNCPs suggests that the p53 tumour-suppressor gene may be a genetic target of environmental carcinogens (Field et al., 1991 (Field et al., , 1992 
mutagen sensitivity From 10% to 40% of patients with head and neck cancer are known to have a high risk of developing second primary neoplasms within a few years following initial diagnosis (Shikhani et al., 1989; Larson et al., 1990; Haughey et al., 1992) . Factors considered responsible for multiple malignancies in head and neck cancer patients remain incompletely understood.
In agreement with the 'field cancerisation' theory (Slaughter et al., 1953) , it is likely that in a fraction of patients with primary cancer of the upper aerodigestive tract prolonged exposure to carcinogens (alcohol, tobacco smoke) could generate genetic changes in the epithelial cells of exposed mucosae, leading to a higher risk of developing second primary malignancies (Franco et al., 1991; Day et al., 1994) . The population at highest risk of multiple primary tumours seems to be genetically predisposed, showing an increased susceptibility to carcinogens, as detected by clastogeninduced chromosome fragility within peripheral blood lymphocytes (Schantz et al., 1990) .
Molecular genetics has provided evidence that mutations in the p53 tumour-suppressor gene are involved in a large number of primary squamous cell carcinomas of the upper aerodigestive tract (Nigro et al., 1989; Sakai and Tsuchida, 1990; Maestro et al., 1992; Caamano et al., 1993; Field et al., 1993) . Moreover, the association between cigarette smoking and p53 gene mutations or overexpression in HNCPs suggests that the p53 tumour-suppressor gene may be a genetic target of environmental carcinogens (Field et al., 1991 (Field et al., , 1992 Cytogenetic studies Chromosome analyses were performed on the three study groups. The test was performed as described previously Schantz and Hsu, 1989; Spitz et al., 1989) , using as mutagen bleomycin sulphate (Sigma, St Louis, MO, USA) at the concentration of 25 Mg ml-'. The number of chromatid breaks counted in each culture was finally converted into the number of chromatid breaks per cell (b/c) to facilitate comparison, as described elsewhere . Multiple chromatid breaks (arrows) in a lymphocyte from a primary blood culture treated with bleomycin sulphate (25 jgml-') in an HNCP with multiple malignancies. first and second primary cancers, whereas six (24%) had positive labelling of the first primary cancer but not of the subsequent second primary, four (16%) patients showed no p53 overexpression in the initial primary but did have positive staining in subsequent primary cancers and six patients (24%) showed no p53 immunoreactivity in both tumours (Table III) (Rarshad et al., 1983; Hsu et al., 1989; Schantz and Hsu, 1989 Recently, it has been reported that mutations in the p53 gene can also reveal an increased susceptibility to cancer owing to inheritance of p53 germline mutations, as frequently occurs in the cancer-prone individuals with Li-Fraumeni syndrome (Harris, 1993) . We demonstrate here that an inherited cancer predisposition expressed by mutagen sensitivity correlates with aberrant p53 gene expression. Thus, differences in such genetic susceptibility and in p53 expression in carcinogen-exposed epithelia of the upper aerodigestive tract might have a major impact in head and neck cancer risk assessment.
Furthermore, we detected p53-positive cells in dysplastic and normal mucosa adjacent to tumour cells in five patients with multiple malignancies. Our data and the identification of p53 overexpression in premalignant lesions of the aerodigestive tract by others (Dolcetti et al., 1992; Wang et al., 1993; Shin et al., 1994) 
